A team of researchers mapping a molecular atlas for ductal carcinoma in situ (DCIS) has made a major advance toward distinguishing whether the early pre-cancers in the breast will develop into invasive cancers or remain stable.
Analyzing samples from patients who had undergone surgery to remove areas of DCIS, the team identified 812 genes associated with cancer progression. Using this gene classifier, they were then able to predict the risk of cancer cells recurring or progressing. The study was published in the journal Cancer Cell.
“There has been a long-standing debate over whether DCIS is cancer or a high-risk condition,” the author said. “In the absence of a way to make that determination, we currently treat everyone with surgery, radiation, or both.
“DCIS is diagnosed in more than 50,000 women a year, and about a third of those women have a mastectomy, so we are increasingly concerned that we might be overtreating many women,” the author said. “We need to understand the biology of DCIS better, and that’s what our research has been designed to do.”
The authors analyzed 774 DCIS samples from 542 patients who were a median of 7.4 years post-treatment. They identified 812 genes associated with recurrence within five years from treatment.
The gene classifier was able to predict both recurrence and invasive progression of cancer, with progression appearing to be dependent on a process that requires interactions between invasive DCIS cells and the unique features of the tumor environment.
The author said most of the DCIS cancers analyzed in the study were identified to be at low risk for cancer progression or recurrence – a factor that underscores the need to have an accurate predictive model that can be used during clinical visits to guide care.
“We’ve made great progress in our understanding of DCIS, and this work gives us a real path forward to being able to personalize care by scaling treatments to the risk of cancer progression,” the author said. “The real goal is diminishing treatment-related harms without compromising outcomes, and we are excited to be getting closer to achieving this for our patients with DCIS.”
https://www.cell.com/cancer-cell/fulltext/S1535-6108(22)00512-8
http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Fmolecular-classification&filter=22
Molecular classification and signatures in breast cancer
- 865 views
- Added
Latest News
Protease action on controll…
By newseditor
Posted 25 May
Maternal inflammation activ…
By newseditor
Posted 25 May
How cells deal with extra c…
By newseditor
Posted 25 May
Flicker stimulation modulat…
By newseditor
Posted 25 May
Multi-dose TB vaccines prot…
By newseditor
Posted 24 May
Other Top Stories
Circuit-specific gene therapy for treating Parkinson's disease
Read more
Monomeric α-synuclein activates the plasma membrane calcium pump
Read more
Brain and heart connections when we pass out?
Read more
Brain link between stress and emotional eating
Read more
Fat cells help repair damaged nerves
Read more
Protocols
Spatially resolved lipidomi…
By newseditor
Posted 24 May
Efficient expansion and CRI…
By newseditor
Posted 21 May
Massively parallel in vivo…
By newseditor
Posted 20 May
Breast cancer-on-chip for p…
By newseditor
Posted 16 May
Methods for making and obse…
By newseditor
Posted 15 May
Publications
Cryo-EM reveals that iRhom2…
By newseditor
Posted 25 May
Fetal brain response to mat…
By newseditor
Posted 25 May
Children born after assiste…
By newseditor
Posted 25 May
Macrophage-induced integrin…
By newseditor
Posted 25 May
Copy number alterations: a…
By newseditor
Posted 25 May
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar